Search
Silodosin
go.drugbank.com/drugs/DB06207ApprovedInvestigational[A231159] Silodosin was first approved by the FDA in October 2008 [A231159] and it is also approved in Europe and Canada. … [A231159] Silodosin works by binding to α<sub>1A</sub>-adrenoceptors with high affinity and relaxing the lower urinary tract, thereby improving urinary symptoms and alleviating bladder outlet obstruction
Bretylium
go.drugbank.com/drugs/DB01158ApprovedRecent evidence has shown that bretylium may also inhibit the Na,K-ATPase by binding to the extracellular K-site. … The primary mode of action for bretylium is thought to be inhibition of voltage-gated K(+) channels.
Teniposide
go.drugbank.com/drugs/DB00444ApprovedInvestigationalTeniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding.
Mafenide
go.drugbank.com/drugs/DB06795ApprovedVet approvedWithdrawnIt acts by reducing the bacterial population present in the burn tissue and promotes healing of deep burns. … In November 2022, the use of mafenide acetate (powder for 5% topical solution) was withdrawn by the FDA due to an unresolved confirmatory study required to fulfill the accelerated approval requirements
Relutrigine
go.drugbank.com/drugs/DB21614InvestigationalRelutrigine is under investigation in clinical trial NCT07010471 (A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine).
ECT-001 expanded cord blood
go.drugbank.com/drugs/DB21745InvestigationalECT-001 expanded cord blood is umbilical cord blood (UCB) that has been co-cultured and expanded with the small molecule agonist [UM-171].
Synonyms: UM-171 expanded cord bloodPropolis wax
go.drugbank.com/drugs/DB11355ApprovedInvestigationalPropolis wax is naturally produced by honeybees by mixing the resin or exudate collected from tree buds, sap flows, or other botanical sources with beeswax that contains fatty acids and bee enzymes.
Pretomanid
go.drugbank.com/drugs/DB05154ApprovedInvestigationalIt was the first TB drug developed by a nonprofit organization, known as TB Alliance, and was granted FDA approval on August 14, 2019.
Tividenofusp alfa
go.drugbank.com/drugs/DB17628ApprovedInvestigationalDeveloped by Denali Therapeutics, tividenofusp alfa received FDA approval on March 25, 2026, under the accelerated approval pathway [L56097, L56099]. … Hunter syndrome is a rare, X-linked lysosomal storage disorder caused by a deficiency in the enzyme iduronate-2-sulfatase (IDS), which leads to the toxic accumulation of glycosaminoglycans (GAGs) throughout
Riluzole
go.drugbank.com/drugs/DB00740ApprovedInvestigationalRiluzole is marketed as Rilutek by Sanofi.